• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by LumiraDx Limited

    2/14/23 4:04:11 PM ET
    $LMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LMDX alert in real time by email
    SC 13D 1 d405390dsc13d.htm SC 13D SC 13D

    CUSIP No. G5709L 109

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    LumiraDx Limited

    (Name of Issuer)

    Common Shares, par value $0.0000028 per share

    (Title of Class of Securities)

    G5709L 109

    (CUSIP Number)

    Morningside Venture Investments Limited

    C/O THC Management Services S.A.M.,

    2nd Floor,

    Le Prince De Galles

    3-5 Avenue Des Citronniers

    Monaco, MC 98000

    011-377-97-97-47-37

    with a copy to:

    Morningside Technology Advisory, LLC

    Attn: Daniel White, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 28, 2022; July 21, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☒

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Morningside Venture Investments Limited

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      WC

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      British Virgin Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Consists of (i) 7,600,284 common shares, par value $0.0000028 per share (“Common Shares”) of the Issuer held by the Morningside Venture Investments Limited (“MVIL”), (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding ordinary shares held by MVIL, which may be voluntarily converted on a one-to-one basis to Common Shares at any time (“Ordinary Shares”), (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 19,864,694 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the Securities and Exchange Commission (the “SEC”) on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      MVIL, LLC

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      WC

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      21,442,525 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      21,442,525

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      21,442,525

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      13.9% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Consists of (i) 19,864,694 Common Shares of the Issuer, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the issuer.

    (2)

    Based on 152,634,554 Common Shares outstanding on December 15, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Frances Anne Elizabeth Richard

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 7,600,284 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 19,864,694 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Jill Marie Franklin

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 7,600,284 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 19,864,694 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Peter Stuart Allenby Edwards

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 7,600,284 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 19,864,694 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Cheung Ka Ho

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Hong Kong

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      54,127,838 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      54,127,838

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,127,838

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 7,600,284 Common Shares of the Issuer held by MVIL, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares held by MVIL, (iii) 788,909 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, (iv) 19,864,694 Common Shares of Issuer held by MVIL, LLC, a wholly owned subsidiary of MVIL and (v) 1,577,831 Common Shares issuable upon exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Cheng Yee Wing Betty

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      New Zealand

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      21,442,525 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      21,442,525

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      21,442,525

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      13.9% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 19,864,694 Common Shares of the Issuer held by MVIL, LLC, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

      (1)    

      Names of Reporting Persons

     

      Wong See Wai

      (2)  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC Use Only

     

      (4)  

      Source of Funds (See Instructions)

     

      AF

      (5)  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or Place of Organization

     

      Hong Kong

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)     

      Sole Voting Power

     

      0

         (8)   

      Shared Voting Power

     

      21,442,525 (1)

         (9)   

      Sole Dispositive Power

     

      0

       (10)   

      Shared Dispositive Power

     

      21,442,525

    (11)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      21,442,525

    (12)  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    (13)  

      Percent of Class Represented by Amount in Row (11)

     

      13.9% (2)

    (14)  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 19,864,694 Common Shares of the Issuer held by MVIL, LLC, and (ii) 1,577,831 Common Shares issuable upon the exercise of warrants of the Issuer held by MVIL, LLC.

    (2)

    Based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022.


    CUSIP No. G5709L 109

     

    Item 1. Security and Issuer.

    This statement on Schedule 13D relates to the Reporting Persons’ (as defined in Item 2 below) beneficial ownership interest in the common shares, par value $0.0000028 per share (the “Common Shares”), of LumiraDx Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Issuer”). The address of the principal executive office of the Issuer is c/o Ocorian Trust (Cayman) Limited, PO Box 1350, Windward 3, Regatta Office Park, Grand Cayman KY1-1108, Cayman Islands. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

    Item 2. Identity and Background.

     

    (a)

    This statement is filed by:

     

      (i)

    Morningside Venture Investments Limited, a British Virgin Islands exempted company (“MVIL”), with respect to the Common Shares directly and beneficially owned by it;

     

      (ii)

    MVIL, LLC, a Delaware limited liability company (“MVIL, LLC”), with respect to the Common Shares directly and beneficially owned by it;

     

      (iii)

    Frances Anne Elizabeth Richard, with respect to the Common Shares beneficially owned by her as a result of her position as a director with MVIL;

     

      (iv)

    Jill Marie Franklin, with respect to the Common Shares beneficially owned by her as a result of her position as a director with MVIL;

     

      (v)

    Peter Stuart Allenby Edwards, with respect to the Common Shares beneficially owned by him as a result of his position as a director with MVIL;

     

      (vi)

    Cheung Ka Ho, with respect to the Common Shares beneficially owned by him as a result of his position as a director with MVIL;

     

      (vii)

    Cheng Yee Wing Betty, with respect to the Common Shares beneficially owned by her as a result of her position as a manager with MVIL, LLC; and

     

      (viii)

    Wong See Wai, with respect to the Common Shares beneficially owned by him as a result of his position as a manager with MVIL, LLC.

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of MVIL and share voting and dispositive power with respect to the securities held by MVIL, including by MVIL, LLC, its wholly owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities held by MVIL and MVIL, LLC. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL, LLC and share voting and dispositive power with respect to the securities held by MVIL, LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL, LLC. MVIL is ultimately wholly beneficially owned by a trust over which Adriel Wenbwo Chan and Wong Yuk Lan share authority to remove the trustee.

     

    (b)

    The business address of each of the Reporting Persons other than MVIL, LLC is:

    c/o THC Management Services S.A.M.,

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers

    MC 98000, Monaco

    With copies to:

    Morningside Technology Advisory, LLC


    CUSIP No. G5709L 109

     

    Attn: Stephanie O’Brien, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    Springfield Financial Advisory Limited

    Attn: Alice Li/Makim Ma

    22nd Floor Hang Lung Centre

    2-20 Paterson Street

    Causeway Bay, Hong Kong

    The business address of MVIL, LLC is:

    22nd Floor Hang Lung Centre, 2-20 Paterson Street

    Causeway Bay, Hong Kong

    With copies to:

    Morningside Technology Advisory, LLC

    Attn: Daniel White, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    Springfield Financial Advisory Limited

    Attn: Alice Li/Makim Ma

    22nd Floor Hang Lung Centre

    2-20 Paterson Street

    Causeway Bay, Hong Kong

     

    (c)

    The present principal business of MVIL, MVIL, LLC, Ms. Richard, Ms. Franklin, Mr. Edwards, Mr. Cheung, Dr. Cheng, Ms. Cheng and Mr. Wong is the venture capital and private equity investment business.

     

    (d)

    No Reporting Person, during the last five years, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)

    No Reporting Person, during the last five years, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)

    Citizenship of the Reporting Persons is as set forth below:

     

    MVIL    British Virgin Islands
    MVIL, LLC    Delaware
    Ms. Richard    United Kingdom
    Ms. Franklin    United Kingdom
    Mr. Edwards    United Kingdom
    Mr. Cheung    Hong Kong
    Ms. Cheng    New Zealand
    Mr. Wong    Hong Kong

    Item 3. Source and Amount of Funds or Other Consideration.

    In 2018, MVIL acquired 55,151 shares of Series A Convertible Preferred Shares of Issuer for an aggregate purchase price of approximately $70.0 million. All such shares were acquired with working capital. Immediately prior to the registration of the Issuer’s Common Shares on September 28, 2021, pursuant to Section 12(b) of the Securities Exchange Act (the “Registration of Securities”), the Series A Convertible Preferred Shares converted into 19,510,977 ordinary shares of Issuer (the “Ordinary Shares”).


    CUSIP No. G5709L 109

     

    In October 2019, MVIL, LLC acquired 5% Convertible Loan Notes from Issuer for an aggregate purchase price of $23.0 million. All such notes were acquired with working capital. Immediately prior to the Registration of Securities, the 5% Convertible Loan Notes automatically converted into 4,537,129 Common Shares.

    In July 2020, MVIL, LLC acquired 10% Convertible Loan Notes from Issuer for an aggregate purchase price of approximately $29.9 million. All such notes were acquired with working capital. Immediately prior to the Registration of Securities, the 10% Convertible Loan Notes automatically converted into 4,990,995 Common Shares.

    In November 2020, MVIL acquired 20,000 shares of Series B Convertible Preferred Shares of Issuer for an aggregate purchase price of $100.0 million. All such shares were acquired with working capital. Immediately prior to the Registration of Securities, the Series B Convertible Preferred Shares converted into 7,600,284 Common Shares.

    The Reporting Persons may be deemed to have acquired beneficial ownership of certain Common Shares on March 28, 2022, which is the date that the Ordinary Shares became convertible into Common Shares in connection with the expiration of certain lock-up restrictions and in accordance with the Amended and Restated Memorandum and Articles of Association of the Issuer.

    On July 21, 2022, MVIL, LLC acquired 10,336,570 Common Shares in a public offering of Issuer for an aggregate purchase price of approximately $18.1 million. All such shares were acquired with working capital.

    Item 4. Purpose of Transaction.

    The securities reported herein were acquired solely for investment purposes with the aim of increasing the value of the investment and the Issuer.

    On July 17, 2018, MVIL entered into a preferred share investor rights letter with the Issuer, pursuant to which MVIL is entitled to one director to Issuer’s board of directors. These appointment rights shall terminate once MVIL sells or no longer controls more than 25% of its initial holding of Series A Convertible Preferred Shares, or Ordinary Shares upon conversion. Lu Huang is the designated director appointee of MVIL. Dr. Huang is not an officer, director, or employee of MVIL and has neither voting nor dispositive control over the shares held by MVIL and does not otherwise beneficially own such shares.

    Item 5. Interest in Securities of the Issuer.

    The aggregate percentage of Common Shares reported beneficially owned by each person named herein is determined in accordance with SEC rules and is based on 152,634,554 Common Shares outstanding on November 7, 2022, as reported in the Issuer’s Current Report on Form 6-K dated December 16, 2022, filed with the SEC on December 16, 2022. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities.

    A. Morningside Venture Investments Limited

     

    (a)

    As of the date hereof, MVIL beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares. MVIL directly holds (i) 7,600,284 Common Shares, (ii) 24,296,120 Common Shares issuable upon the conversion of outstanding Ordinary Shares, and (iii) 788,909 Common Shares issuable upon the exercise of warrants, and MVIL, LLC, its wholly owned subsidiary, holds 19,864,694 Common Shares and 1,577,831 Common Shares issuable upon exercise of warrants.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      54,127,838  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      54,127,838  


    CUSIP No. G5709L 109

     

    B.

    MVIL, LLC

    (a) As of the date hereof, MVIL, LLC beneficially owns 21,442,525 shares of Common Shares, representing a beneficial ownership of approximately 13.9% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      21,442,525  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      21,442,525  

    C. Frances Anne Elizabeth Richard

    (a) As of the date hereof, Ms. Richard beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      54,127,838  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      54,127,838  

     

    D.

    Jill Marie Franklin

    (a) As of the date hereof, Ms. Franklin beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      54,127,838  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      54,127,838  

     

    E.

    Peter Stuart Allenby Edwards

    (a) As of the date hereof, Mr. Edwards beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      54,127,838  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      54,127,838  

     

    F.

    Cheung Ka Ho

    (a) As of the date hereof, Mr. Cheung beneficially owns 54,127,838 shares of Common Shares, representing a beneficial ownership of approximately 30.2% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      54,127,838  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      54,127,838  

     

    G.

    Cheng Yee Wing Betty

     

    (a)

    As of the date hereof, Ms. Cheung beneficially owns 21,442,525 shares of Common Shares, representing a beneficial ownership of approximately 13.9% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      21,442,525  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      21,442,525  


    CUSIP No. G5709L 109

     

    H.

    Wong See Wai

     

    (a)   As of the date hereof, Mr. Cheung beneficially owns 21,442,525 shares of Common Shares, representing a beneficial ownership of approximately 13.9% of the Common Shares.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      21,442,525  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      21,442,525  

    (c) See Item 3.

    (d) Not applicable.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Amended and Restated Articles of Incorporation

    The Amended and Restated Memorandum and Articles of Association of the Issuer contain lock-up restrictions on the Ordinary Shares. To be transferrable, the Ordinary Shares must first be voluntarily converted into Common Shares. Voluntary conversion became permissible on March 28, 2022.

    Amended and Restated Registration Rights Agreement

    On September 28, 2021, MVIL and MVIL, LLC entered into an amended and restated registration rights agreement with the Issuer, CA Healthcare Acquisition Corp., a Delaware corporation (“CAH”), CA Healthcare Sponsor LLC, a Delaware limited liability company, and other equityholders of the Issuer (the “Amended and Restated Registration Rights Agreement”). Pursuant to the Amended and Restated Registration Rights Agreement, MVIL and MVIL, LLC, as holders of registrable securities of the Issuer, are entitled to registration rights. MVIL and MVIL, LLC are entitled to make up to an aggregate of three demands, excluding short-form demands, that the Issuer register their registrable securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of the merger of Issuer’s wholly-owned subsidiary and CAH. The Registration Rights Agreement also provides that the Issuer will pay certain expenses related to such registrations and indemnify securityholders against certain liabilities.

    Item 7. Material to be Filed as Exhibits.

    The following documents are filed as Exhibits to this statement:

     

    Exhibit

    Number

      

    Exhibit Description

    99.1    Joint Filing Agreement
    99.2    Amended and Restated Memorandum and Articles of Association of the Issuer (filed as Exhibit 1.1 to the Issuer’s Report on Form 20-F dated December 31, 2021, filed with the SEC on April 13, 2022 and incorporated herein by reference).
    99.3    Amended and Restated Registration Rights Agreement by and among LumiraDx Limited, CAH, Sponsor and the other parties named therein (filed as Exhibit 4.4 to the Issuer’s Report on Form 20-F dated September 28, 2021, filed with the SEC on September 29, 2021 and incorporated herein by reference).


    CUSIP No. G5709L 109

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

    Dated: February 14, 2023

     

    For and on behalf of
    MORNINGSIDE VENTURE INVESTMENTS LIMITED
    By:  

    /s/ Frances Anne Elizabeth Richard

      Frances Anne Elizabeth Richard, Director
    For and on behalf of
    MVIL, LLC
    By:  

    /s/ Cheng Yee Wing Betty

      Cheng Yee Wing Betty, Manager

    /s/ Frances Anne Elizabeth Richards

    Frances Anne Elizabeth Richards

    /s/ Jill Marie Franklin

    Jill Marie Franklin

    /s/ Peter Stuart Allenby Edwards

    Peter Stuart Allenby Edwards

    /s/ Cheung Ka Ho

    Cheung Ka Ho

    /s/ Cheng Yee Wing Betty

    Cheng Yee Wing Betty

    /s/ Wong See Wai

    Wong See Wai

     

    Get the next $LMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMDX

    DatePrice TargetRatingAnalyst
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    11/15/2021$20.00Outperform
    Evercore ISI Group
    10/27/2021$12.00Buy
    BTIG Research
    10/25/2021$13.00Outperform
    Raymond James
    More analyst ratings

    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/12/24 4:06:57 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)

      SC 13G/A - LumiraDx Ltd (0001685428) (Subject)

      2/9/24 4:16:20 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by LumiraDx Limited (Amendment)

      SC 13D/A - LumiraDx Ltd (0001685428) (Subject)

      12/29/23 1:52:49 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    SEC Filings

    See more
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      2/6/24 4:34:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/29/23 4:26:15 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by LumiraDx Limited

      6-K - LumiraDx Ltd (0001685428) (Filer)

      12/8/23 7:15:38 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on LumiraDx with a new price target

      Raymond James reiterated coverage of LumiraDx with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      3/11/22 7:22:18 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Evercore ISI Group initiated coverage on LumiraDx with a new price target

      Evercore ISI Group initiated coverage of LumiraDx with a rating of Outperform and set a new price target of $20.00

      11/15/21 8:56:20 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • BTIG Research initiated coverage on LumiraDx with a new price target

      BTIG Research initiated coverage of LumiraDx with a rating of Buy and set a new price target of $12.00

      10/27/21 8:35:45 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

      LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (NASDAQ:LMDX)(the "Company") received a notice ("Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimu

      10/27/23 4:45:02 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Financials

    Live finance-specific insights

    See more
    • LumiraDx Reports Second Quarter 2023 Results

      LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 millionSubmitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra testSubmitted COVID/Flu combo test for FDA Emergency Use Authorization (EUA) as part of the NIH's Independent Test Assessment (ITAP) programMore than 1,500 new instruments shipped in Q2, primarily to U.S. pharmacy locations to expand testing capacity for the upcoming respiratory season Ron Zwanziger, Chairman and CEO of LumiraD

      8/24/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

      LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.    LumiraDx Second Quarter 2023 Financial Results Conference Call  Date:Thursday, August 24, 2023Time:8:30 AM Eastern Time   Live Call/Webcast:   Register to join by phone here.  View webcast: https://investors.lumiradx.com/news-and-events/investor-calendar    A replay of the webcast will be available on the Inv

      8/16/23 4:30:00 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Reports First Quarter 2023 Results

      LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.Cost reduction programs implemented across the global organization resulting in declining operating losses.US Clinical Studies for first 510K submission completed.More than 100 customers in the first full launch quarter for the world's first quantitative finger stick NT-proBNP assay. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, "Our transition to non-COVID is beginning to develop, especially with the commercial launches of HbA1c

      5/16/23 7:45:00 AM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

      LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards. As previously disclosed, on October 24, 2023, the Company received a notice from Nasdaq's Listing Qualifications Department (the "Staff") stating that the Company's securities were subject to delisting from The Nasdaq Global Market due to a failure to maintain compliance with the minimum bid price requirement of Nasd

      1/5/24 5:45:23 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

      LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX) (the "Company"), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche. The Company announced today that Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting LLP have been appointed as joint administrators of two of its subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the Lumi

      12/29/23 4:15:50 PM ET
      $LMDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care